Progress in the development of alternative pharmaceutical formulations of taxanes

Investigational New Drugs

Volumn 19, Issue 2, 2001, Pages 143-153

  Nuijen, Bastiaan ^a,b   Bouma, Marjan ^a,b   Schellens, Jan H M ^a,b   Beijnen, Jos H ^a,b  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Alternative formulation; Co solvents; Cyclodextrines; Docetaxel; Emulsions; Liposomes; Microencapsulation systems; Paclitaxel; Prodrugs; Surfactants; Taxanes

Indexed keywords

ALCOHOL; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; CREMOPHOR; CYCLODEXTRIN; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; PACLITAXEL; PNU 166945; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER INHIBITION; CLINICAL TRIAL; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MICROENCAPSULATION; NEUROTOXICITY; OVARY CANCER; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHEMISTRY, PHARMACEUTICAL; CYCLODEXTRINS; DRUG COMPOUNDING; EMULSIONS; HUMANS; NEOPLASMS; PACLITAXEL; PRODRUGS; SOLVENTS; SURFACE-ACTIVE AGENTS; TAXOIDS;

EID: 0035025093     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1010682916808     Document Type: Article

References (55)

1. Taxanes: A new class of antitumor agents
2. Biopharmaceutics of paclitaxel (Taxol): Formulation, activity, and pharmacokinetics
3. Taxol: A history of pharmaceutical development and current pharmaceutical concerns
4. Alternative formulations of paclitaxel
5. Hypersensitivity reactions to the taxanes paclitaxel and docetaxel
6. Histamine release in dogs by Cremophor EL® and its derivatives: Oxethylated oleic acid is the most effective constituent
7. Paclitaxel formulation as a cause of ethanol intoxication
8. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL
9. Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients
10. The influence of Cremophor EL on the cell cycle effects of paclitaxel (Taxol) in human tumor cell lines
11. Pharmaceutical properties of paclitaxel and their effects on preparation and administration
12. Pharmaceutical development of (investigational) anticancer agents for parenteral use - A review
13. Solubility principles and practices for parenteral drug dosage form development
14. Human plasma distribution of free paclitaxel and paclitaxel associated with diblock copolymers
15. An investigation of the antitumour activity and biodistribution of polymeric micellar paclitaxel
16. Anti-tumor efficacy and biodistribution of intravenous polymeric micellar paclitaxel
17. A new parenteral emulsion for the administration of Taxol
18. Emulsion formulations for intavenous administration of paclitaxel
19. A submicron lipid emulsion coated with amphipathic polyethylene glycol for parenteral administration of paclitaxel (Taxol)
20. Development of nonionic surfactant/phospholipid o/w emulsion as a paclitaxel delivery system
21. In vitro and in vivo antitumoral activity of free, and encapsulated taxol
22. Novel Taxol formulation: Polyvinylpyrrolidone nanoparticle-encapsulated Taxol for drug delivery in cancer therapy
23. Taxol encapsulation in poly(ε-caprolactone) microspheres
24. Controlled delivery of taxol from microspheres composed of a blend of ethylene-vinyl acetate copolymer and poly (d,l-lactic acid)
25. Enhanced efficacy of a novel controlled release paclitaxel formulation (PACLIMER Delivery System) for local-regional therapy of lung cancer tumor nodules in mice
26. A mixed micellar formulation suitable for the parenteral administration of Taxol
27. Novel Taxol formulations: Taxol containing liposomes
28. Novel Taxol formulations: Preparation and characterization of Taxol-containing liposomes
29. Activity of paclitaxel liposome formulations against human ovarian tumor xenografts
30. Cyclodextrins in the pharmaceutical field
31. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization
32. Pharmaceutical and physical properties of paclitaxel (Taxol) complexes with cyclodextrines
33. Preparation and biological activity of taxol acetates
34. Synthesis and antitumor evaluation of water soluble taxol phosphates
35. Paclitaxel (Taxol®) formulation and prodrugs
36. Novel water soluble phosphate prodrugs of Taxol® possessing in vivo antitumor activity
37. Synthesis and antitumor evaluation of 2′-oxycarbonylpaclitaxels (paclitaxel-2′-carbonates)
38. Synthesis and evaluation of some water-soluble prodrugs and derivatives of Taxol with antitumor activity
39. New active paclitaxel amino acids derivatives with improved water solubility
40. Design, synthesis and biological activity of protaxols
41. Highly water-soluble taxol derivatives: 2′-polyethyleneglycol esters as potential prodrugs
42. Drug delivery systems: Water soluble Taxol 2′-poly(ethylene glycol) ester prodrugs-design and in vivo effectiveness
43. Synthesis and evaluation of water-soluble polyethylene glycol-paclitaxel conjugate as a paclitaxel prodrug
44. Antitumor activity of paclitaxel-2′-glycinate conjugated to poly(ethylene glycol): A water soluble prodrug
45. Preparation and characterization and properties in vitro and in vivo of a paclitaxel-albumin conjugate
46. Synthesis and biological activity of water soluble polymer-bound taxol derivatives
47. Structure-activity relationships of new taxoids derived from 14β-hydroxy-10-deacetylbaccatin III
48. Novel cytotoxic 3′-(tert-butyl) 3′-diphenyl analogs of paclitaxel and docetaxel
49. Preclinical in vivo efficacy of two 9-dihydrotaxane analogues against human and murine tumors
50. Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble drugs
51. Development of a polymeric surgical paste formulation for taxol
52. Intratumoral chemotherapy with sustained-release drug delivery system inhibits growth of human pancreatic cancer xenografts
53. Co-administration of cyclosporin enables oral therapy with paclitaxel